Edward J. Benz's most recent trade in Candel Therapeutics Inc was a trade of 14,240 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 17, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Candel Therapeutics Inc | Edward J. Benz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 14,240 | 14,240 | - | - | Stock Option (Right to Buy) | |
| Candel Therapeutics Inc | Edward J. Benz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2024 | 14,240 | 14,240 | - | - | Stock Option (Right to Buy) | |
| Candel Therapeutics Inc | Edward J. Benz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2023 | 14,240 | 14,240 | - | - | Stock Option (Right to Buy) | |
| Deciphera Pharmaceuticals Inc | Edward J. Benz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Candel Therapeutics Inc | Edward J. Benz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2022 | 14,240 | 14,240 | - | - | Stock Option (Right to Buy) | |
| Deciphera Pharmaceuticals Inc | Edward J. Benz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Deciphera Pharmaceuticals Inc | Edward J. Benz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2021 | 12,000 | 12,000 | - | - | Stock Option (Right to Buy) |